<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03312751</url>
  </required_header>
  <id_info>
    <org_study_id>NI-0501-09</org_study_id>
    <nct_id>NCT03312751</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis</brief_title>
  <official_title>An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess Its Efficacy, Safety, Impact on Quality of Life, and Long-term Outcome in Pediatric Patients With Primary Hemophagocytic Lymphohistiocytosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swedish Orphan Biovitrum</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swedish Orphan Biovitrum</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to expand the knowledge on the efficacy and safety of emapalumab&#xD;
      (previously known as NI-0501) as a treatment for primary haemophagocytic lymphohistiocytosis&#xD;
      (HLH) patients, with special focus on long-term outcome and quality of life assessments.&#xD;
      Emapalumab can be administered as the first-line therapy, to patients not previously treated&#xD;
      with the current standard of care, or can be given to patients who have either failed or were&#xD;
      unable to tolerate the available standard of care.&#xD;
&#xD;
      Emapalumab is to be administered until the start of conditioning, with an anticipated&#xD;
      duration ranging from a minimum of 4 weeks to approximately 12 weeks and not exceeding 6&#xD;
      months.&#xD;
&#xD;
      After treatment completion, patients will continue in the study for long-term follow-up until&#xD;
      1 year after either HSCT or last emapalumab infusion (if HSCT is not performed).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 5, 2019</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response at Week 8 or End of Treatment (if earlier)</measure>
    <time_frame>Up to Week 8</time_frame>
    <description>Achievement of either Complete or Partial Response or HLH Improvement, at Week 8 or EOT (whichever occurs earlier)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Including survival to HSCT and post-HSCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients proceeding to HSCT</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Number of patients proceeding to HSCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PedsQL Score</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Assessment of the quality of life using the PedsQL &quot;Pediatric Quality of Life Inventory&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence, severity, causality and outcomes of AEs (serious and non-serious)</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Incidence of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Incidence of circulating antibodies against emapalumab</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall Response at start of conditioning</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Achievement of either Complete or Partial Response or HLH Improvement, at start of conditioning</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum concentrations of emapalumab</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Serum concentrations of emapalumab</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacodynamic parameters</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Levels of total IFNγ, markers of its neutralization (CXCL9 and CXCL10) and other relevant disease biomarkers e.g. sCD25</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Primary Hemophagocytic Lymphohistiocytosis</condition>
  <arm_group>
    <arm_group_label>Emapalumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emapalumab</intervention_name>
    <description>Emapalumab will be administered by intravenous infusion, twice weekly.</description>
    <arm_group_label>Emapalumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary HLH patients with active disease.&#xD;
&#xD;
          -  Treatment naïve patients or patients having already received HLH conventional therapy,&#xD;
             but having failed or unable to tolerate current standard of care.&#xD;
&#xD;
          -  Informed consent signed by the patient or by the patient's legally authorized&#xD;
             representative.&#xD;
&#xD;
          -  Guidance on contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of secondary HLH consequent to a proven rheumatic, metabolic or neoplastic&#xD;
             disease.&#xD;
&#xD;
          -  Active Mycobacteria, Histoplasma Capsulatum, Shigella, Salmonella, Campylobacter or&#xD;
             Leishmania infections.&#xD;
&#xD;
          -  Evidence of latent tuberculosis.&#xD;
&#xD;
          -  Presence of malignancy.&#xD;
&#xD;
          -  Concomitant disease or malformation severely affecting cardiovascular, pulmonary,&#xD;
             central nervous system (CNS), liver, or renal function, that in the opinion of the&#xD;
             Investigator may significantly affect the likelihood to respond to treatment and/or&#xD;
             the assessment of emapalumab safety and/or efficacy&#xD;
&#xD;
          -  History of hypersensitivity or allergy to any component of the study regimen&#xD;
&#xD;
          -  Receipt of a BCG vaccine within 12 weeks prior to Screening&#xD;
&#xD;
          -  Receipt of a live or attenuated live (other than BCG) vaccine within 6 weeks prior to&#xD;
             Screening&#xD;
&#xD;
          -  Pregnant or lactating female patients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Phoenix Children Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045-7106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred I. duPont Hospital for Children - Nemours Center for Cancer and Blood Disorders - Division of Pediatric Hematology Oncology</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute (DFCI)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Health Helen Devos Children's Hospital</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Ste-Justine Research Center</name>
      <address>
        <city>Montréal</city>
        <zip>QC H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <zip>ON M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's and Women's Health Centre of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center- University of Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Giannina Gaslini</name>
      <address>
        <city>Genova</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione MBBM, Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesu</name>
      <address>
        <city>Rome</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale della Donna e del Bambino</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Niño Jesús</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital Zurich - Eleonorenstiftung</name>
      <address>
        <city>Zürich</city>
        <zip>CH-8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital Zurich</name>
      <address>
        <city>Zürich</city>
        <zip>CH-8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Children Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS13EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 5, 2017</study_first_submitted>
  <study_first_submitted_qc>October 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2017</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Interferon-gamma</keyword>
  <keyword>NI-0501</keyword>
  <keyword>primary HLH</keyword>
  <keyword>emapalumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphohistiocytosis, Hemophagocytic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

